CLASS II ONGOING Drug recall · Reported 29 Jul 2026 · FDA Enforcement Report
Naropin (ropivacaine hydrochloride Injection, USP) recalled
Fresenius Kabi USA is recalling Naropin (ropivacaine hydrochloride Injection, USP), 5%, 100 mg per (5 mg per mL), distributed nationwide in the US. The recall was initiated on 16 Jul 2026 and the FDA has classified it as Class II.
Check your package
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
Recall details
- Recall number
- D-0727-2026
- FDA event ID
- 99449
- Recalling firm
- Fresenius Kabi USA, Lake Zurich, IL
- Brand
- Naropin
- Manufacturer
- Fresenius Kabi USA, LLC
- Classification
- Class II
- Status
- Ongoing
- Recall initiated
- 16 Jul 2026
- FDA classified
- 23 Jul 2026
- Reported
- 29 Jul 2026
- Type
- Voluntary: Firm initiated
- Customers notified by
- Letter
- Reason category
- Particulate Matter
- Drug class
- Injectable & IV Drugs
Timeline
| 16 Jul 2026 | Recall initiated by company | |
| 23 Jul 2026 | Classified by FDA | +7 days |
| 29 Jul 2026 | Published in enforcement report | +6 days |
Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.
Reason for recall
Presence of Particulate Matter: Hair was found in products
Product as listed by the FDA
Naropin (ropivacaine hydrochloride Injection, USP), 0.5%, 100 mg per 20 mL (5 mg per mL), Twenty-five, 20 mL Single-Dose Vials, Rx only, Fresenius Kabi, Lake Zurich, IL 60047 NDC Tray: 63323-286-23; NDC Vial: 63323-286-05
Where it was distributed
Nationwide within in the USA
Questions about this recall
Is Naropin (ropivacaine hydrochloride Injection, USP), 5%, 100 mg per (5 mg per mL) recalled?
Yes. Fresenius Kabi USA recalled Naropin (ropivacaine hydrochloride Injection, USP), 5%, 100 mg per (5 mg per mL) on 16 Jul 2026. The recall is Class II and its status is Ongoing. Recall number D-0727-2026.
Why was it recalled?
Presence of Particulate Matter: Hair was found in products
Which lots are affected?
Lot #: 6133436, Exp. Date 10/2028
Where was it sold?
Nationwide within in the USA
What should I do if I have it?
Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.
What does Class II mean?
Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.
Read the official FDA notice · Source record retrieved 21 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.
More recalls from Fresenius Kabi USA
All 94| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS I | Tyenne (tocilizumab-aazg) Injection, 400 mg/ (20 mg/mL) vial recalledTyenne | Fresenius Kabi USA | Particulate Matter | Nationwide |
| Drug | CLASS I | Morphine Sulfate Injection recalled by Fresenius Kabi USAMorphine Sulfate | Fresenius Kabi USA | Packaging Defects | Nationwide |
| Drug | CLASS II | Glycopyrrolate Injection, USP, 1 mg per 2 mg per mL) recalledGlycopyrrolate | Fresenius Kabi USA | Particulate Matter | Nationwide |
| Drug | CLASS II | Xylocaine (lidocaine HCl Injection, USP), 1%, 500 mg recalledXylocaine | Fresenius Kabi USA | Particulate Matter | Nationwide |
| Drug | CLASS II | Lidocaine HCl Injection, USP, 2%, 100 mg recalled by Fresenius Kabi USALidocaine | Fresenius Kabi USA | Particulate Matter | Nationwide |
Other Ropivacaine recalls
All 5| Reported | Class | Recall | Company | Reason | Where |
|---|---|---|---|---|---|
| Drug | CLASS I | Ropivacaine Hydrochloride Injection, USP, 5%, 500 mg per (5mg/mL) recalledRopivacaine Hydrochloride | Amneal Pharmaceuticals | Particulate Matter | Nationwide |
| Drug | CLASS II | Ropivacaine Hydrochloride Injection USP, 5%, 150mg recalled by Akorn | Akorn | Potency & Assay | Nationwide |
| Drug | CLASS II | Ropivacaine Hydrochloride Injection USP, 2%, 200mg/ (2 mg/mL) Vial recalled | Akorn | Potency & Assay | Nationwide |
| Drug | CLASS II | Ropivacaine HCl Injection in all strengths, all doses recalled | Pharmedium Services | Sterility | Nationwide |